Like last year, Mutabilis delegates will participate to the Berlin Conference on Novel Antimicrobials and Diagnosstics 2019 on March 14th – 15th 2019. https://amr-conference.com/home/
The Antimicrobial Resistance (AMR) is the natural process of evolution through which bacteria develop resistance when they are confronted to antibiotics, rendering the available treatments inoperative. There is therefore a balance to achieve between the development rate of bacterial resistance and the rate at which we develop new antibiotics, since the more we use them the less effective they become. However, the lack of market incentives and the scientific challenges met in developing new antibiotics have triggered a divestment of many pharmaceutical companies towards other therapeutic fields, causing the development of new antibiotics to stall in the last decades.
Today we are reaching a point where the resistance is threatening to leave us short of therapeutic options against infections by increasingly resistant pathogens such as the carbapenem resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa. In the US alone more than 2 million people a year are subject to antibiotic-resistant infections causing more than 23 000 dead. In Europe the death toll reaches 25 000 per year. By 2050 if the AMR issue is not tackled we could have 10 million deaths a year according to the most recent estimates.
Innovative antibiotics are urgently needed to provide treatment against the most worrying resistant pathogens. But if we consider the bigger picture there is also a strong need for controlling the use of antibiotics and providing alternatives to antibiotics as they are used today.
The rise in bacterial resistance to antibiotics today constitutes a public health challenge. The lack of R&D investment in the sector for decades has led to pipeline attrition, and the widespread use of available antibiotics has fostered the emergence of resistant bacteria, against which we have treatments that are increasingly less effective.
The new class of antibiotics are those best placed to compensate for the loss of activity in older treatments rendered ineffective by the evolution of resistance. But in a global approach, it is also important to control the use of antibiotics and encourage the development of all alternatives that allow for decreased reliance on antibiotic treatments. Ideally, these approaches would not exert evolutionary pressure susceptible to causing the emergence of resistance. And they would allow for reliance on antibiotics to be limited to the most serious cases.
Founded in 2001, MUTABILIS is a spin-off of INSERM, based on the work of Professor Xavier Nassif’s team, pioneer in the identification of virulence genes in the Neisseria Meningitidis. These studies were then transposed to all Gram – bacteria, then to Gram+ bacteria.